Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects

NCT07015671 is registered in ClinicalTrials.gov with Sarfez Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07015671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07015671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2025
Completion date
December 30, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence study in healthy subjects, pk/pd